Skip to main content
. 2017 Mar 9;8(20):33002–33013. doi: 10.18632/oncotarget.16031

Figure 4.

Figure 4

(A) shows Western blot for IKKβ and Tubulin expression in MCF7 ER positive cells, C is untreated cells, Lipo is cells treated only with lipofectamine, NT siRNA is cells treated with non-targeting siRNA, IKKα siRNA is cells treated with siRNA for IKKα and IKKβ siRNA is cells treated with siRNA for IKKβ. Western blot shows that only siRNA for IKKβ lowers IKKβ expression. (B) shows plots for fold change in apoptosis levels in MCF7 cells and MDA-MB-231 cells treated with lipofectamine (C) non-targeting siRNA (NT) and IKKβ siRNA. (C) shows plots for fold change in cell viability levels in MCF-7 cells and MDA-MB 231 cells treated with lipofectamine (C), non-targeting siRNA (NT) and IKKβ siRNA. (D) shows xCELLigence cell index plots for MCF7 cells and MDA-MB 231 cells treated with lipofectamine (C), non-targeting siRNA (NT) and IKKβ siRNA.